Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
Zacks에서 열기
Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zimmer Biomet (ZBH) reported $2.06 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 3.1%. EPS of $1.90 for the same period compares to $1.90 a year ago.

The reported revenue represents a surprise of +0.81% over the Zacks Consensus Estimate of $2.05 billion. With the consensus EPS estimate being $1.89, the EPS surprise was +0.53%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Zimmer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- United States: $1.21 billion compared to the $1.19 billion average estimate based on two analysts. The reported number represents a change of +3.6% year over year. Net Sales- International: $857.2 million versus the two-analyst average estimate of $848.09 million. The reported number represents a year-over-year change of +2.4%. Net Sales- Hips- International: $256.4 million versus $244.01 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.2% change. Net Sales- Knees- International: $336.3 million compared to the $352.41 million average estimate based on two analysts. The reported number represents a change of -4.5% year over year. Net Sales- Hips- United States: $280.1 million versus $273.95 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.8% change. Net Sales- Knees- United States: $431.3 million compared to the $445.6 million average estimate based on two analysts. The reported number represents a change of -2% year over year. Net Sales- Knees: $767.5 million versus $790.99 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -3.1% change. Net Sales- Technology & Data, Bone Cement and Surgical: $180.6 million versus $168.14 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +12% change. Net Sales- S.E.T: $578.3 million versus the five-analyst average estimate of $558.36 million. The reported number represents a year-over-year change of +6.8%. Net Sales- Hips: $536.5 million compared to the $518.4 million average estimate based on five analysts. The reported number represents a change of +6% year over year.

View all Key Company Metrics for Zimmer here>>>

Shares of Zimmer have returned +8.2% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research